IMNM

Rating neutralAI Memo

Immunome

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

IM-1340 Phase 1 initiation • 2026-12-31

Base target: $20 / p=0% prob

Biggest risk

Regulatory, clinical and launch outcomes remain uncertain. IM-1340 has not yet generated human data, while multiple trials and preparations for a potential launch require sustained spending.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

The RINGSIDE efficacy results and accepted NDA support a potential varegacestat approval; IM-1021 data and newly IND-cleared IM-1340 offer additional, less-proven pipeline options. [#SEC-8K-2026-08-11] [#IR-2026-09-30]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

$20

p=0%

Bull target

$31

p=0%

Bear target

$12

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Initial IM-1021 lymphoma data
The RINGSIDE efficacy results and accepted NDA support a potential varegacestat approval; IM-1021 data and newly IND-cleared IM-1340 offer additional, less-proven pipeline options.
[#SEC-8K-2026-08-11] [#IR-2026-09-30]

BearKey bullets

Early-stage ADC and radioligand programs face enrollment, safety and efficacy risk; IM-1340 preclinical activity may not translate to patients.
[#IR-2026-09-30]
Immunome reported $520.0 million in cash, equivalents and marketable securities at June 30, 2026 and expected funding into 2028, while Q2 R&D expense was $59.9 million.

WatchKey bullets

IM-1340 Phase 1 initiation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $20 (p=0%)

Target spread vs base: +59% / -38%

Scenario probabilities

Bull Target: $31 (p=0%)Base Target: $20 (p=0%)Bear Target: $12 (p=0%)

Commentary

The September 30 IND clearance adds a confirmed pipeline milestone, but the packet does not establish its sustained share-price effect. Analyst revisions, options skew, short interest, employee sentiment and sufficient social coverage are unavailable; sentiment zeros are placeholders, not measured neutral readings. The deterministic prior remains negative, so this is an event-driven monitoring view rather than a strong bullish call.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Regulatory, clinical and launch outcomes remain uncertain. IM-1340 has not yet generated human data, while multiple trials and preparations for a potential launch require sustained spending.

Drivers

Scannable catalysts and supporting factors

Initial IM-1021 lymphoma data

Scenarios

Bull Target (Scenario probability)

$31 / p=0% prob

Base Target (Scenario probability)

$20 / p=0% prob

Bear Target (Scenario probability)

$12 / p=0% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
IM-1340 Phase 1 initiation
Immunome announced FDA IND clearance for its IM-1340 antibody-drug conjugate on September 30 and expects to begin a first-in-human solid-tumor study in Q4 2026. Clearance permits clinical testing; the reported antitumor activity is preclinical, not evidence of patient benefit. [#IR-2026-09-30] https://investors.immunome.com/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors/
Prob 75.00% • Move 5.00% • Priced-in 65.00%
EVENT2026-12-31
European varegacestat submission
Immunome plans to submit a varegacestat marketing application in Europe by year-end 2026. Submission would demonstrate execution, not constitute approval. [#8-K-2026-08-11] [#SEC-8K-2026-08-11]
Prob 75.00% • Move 5.00% • Priced-in 60.00%
EVENT2027-04-28
FDA varegacestat decision
The FDA accepted the desmoid-tumor NDA and set an April 28, 2027 target action date. Phase 3 RINGSIDE met its primary and key secondary endpoints, but approval, labeling and launch execution remain uncertain. [#SEC-8K-2026-08-11]
Prob 78.00% • Move 30.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Initial IM-1021 lymphoma data
2026-12-31
Immunome expects initial Phase 1 lymphoma data in 2026 and has reported objective responses at multiple dose levels. Response durability, safety and breadth remain to be established. [#SEC-8K-2026-08-11]
Prob 65% • Move 15% • Priced-in 35%

Risks

Early-stage ADC and radioligand programs face enrollment, safety and efficacy risk; IM-1340 preclinical activity may not translate to patients. [#IR-2026-09-30]
Immunome reported $520.0 million in cash, equivalents and marketable securities at June 30, 2026 and expected funding into 2028, while Q2 R&D expense was $59.9 million. Spending and future financing needs warrant monitoring. [#PR-EARNINGS-2026-08-11]
September and August Form 4 records include open-market insider sales; they do not establish operating deterioration. [#SEC-FORM4-2026-09-15] [#SEC-FORM4-2026-08-12]
Varegacestat approval, label scope, reimbursement and launch uptake remain uncertain despite positive Phase 3 results and an accepted NDA. [#SEC-8K-2026-08-11]

Peers

Symbol	Summary
IRON	Similar supplied market capitalization and development-stage biopharma exposure, but not an established direct desmoid-tumor or product peer.
NRIX	Similar supplied market capitalization and oncology-development exposure; modality and indication differences make it a loose valuation comparator, not a direct peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

IRON

Similar supplied market capitalization and development-stage biopharma exposure, but not an established direct desmoid-tumor or product peer.

NRIX

Similar supplied market capitalization and oncology-development exposure; modality and indication differences make it a loose valuation comparator, not a direct peer.